BB Biotech AG Releases 2025 Annual Report

BB Biotech AG has unveiled its annual report for the fiscal year 2025. The report details the company's robust performance in the biotechnology sector, alongside its investment strategy and portfolio coverage. Notably, BB Biotech shares achieved a substantial total return of +34.2% in CHF, +37.0% in EUR, and +53.7% in USD, factoring in a CHF 1.80 dividend paid in March 2025.

The net asset value (NAV) performance also exhibited significant growth, recording +26.5% in CHF, +27.8% in EUR, and +44.8% in USD. The year closed with a full-year net profit of CHF 578 million, a notable increase from the CHF 76 million reported in 2024.

In line with its consistent dividend policy, BB Biotech AG intends to propose a dividend of CHF 2.25 per share. This represents a 5% yield based on December 2025's average share price, to be discussed at the upcoming Annual General Meeting.